The DOI matches its Crossref record; 12 of the 12 references it cites were found in a registry or an index.
Liraglutide, a Long-Acting Human Glucagon-Like Peptide-1 Analog, Given as Monotherapy Significantly Improves Glycemic Control and Lowers Body Weight Without Risk of Hypoglycemia in Patients With Type 2 Diabetes
Open accessAbstract
iraglutide is a long-acting human glucagon-like peptide-1 (GLP-1) analog (1-4), and the current study was undertaken to evaluate efficacy and safety after 14 weeks' treatment with liraglutide in patients with type 2 diabetes. RESEARCH DESIGN AND METHODS-Main inclusion criteria were patients aged Ն18 years with type 2 diabetes and A1C Ն7.5 and Յ10.0% (diet) or Ն7.0 and Յ9.5% (mono-oral antidiabetes drug); previous therapy was discontinued.Fasting plasma glucose (FPG) at randomization was 7-13 mmol/l.If FPG was Ͼ15 mmol/l during the study, the patient was withdrawn.The study was conducted in accordance with the Declaration of Helsinki (5).The study was double-blind, randomized (1:1:1:1), and placebo-controlled using three doses of liraglutide (0.65, 1.25, or 1.90 mg).The following main efficacy parameters were assessed: A1C, insulin, proinsulin, glucagon, fructosamine, lipids, homemeasured seven-point plasma glucose profiles, and body weight.Safety parameters (adverse events, hypoglycemic episodes, clinical laboratory parameters, antibodies against liraglutide, vital signs, electrocardiogram, and thyroid (including ultrasonography) and parathyroid parameters were assessed.Liraglutide or placebo was administered in the evening (as in the most recently completed phase 2 study) (6) as once-daily subcutaneous injections in the abdomen or thigh.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Turner, R. C., Fox, C., Matthews, McElroy, H. H., Cull, C. A., Holman, R. R., Neil, P., Hadden, D. R., Wright, D., Manley, E., et al. (1998) · The Lancet · Cited by 8,419
Standards of Medical Care in Diabetes–2006
American Diabetes Association (2006) · Diabetes Care · doi:10.2337/diacare.29.s1.06.s4 · Cited by 1,885
Knudsen, L. B., Nielsen, P. F., Huusfeldt, P. O., Johansen, N. L., Madsen, K., Pedersen, F. Z., Thøgersen, H., Wilken, M., & Agersø, H. (2000) · Journal of Medicinal Chemistry · doi:10.1021/jm9909645 · Cited by 700
(1997) · JAMA · doi:10.1001/jama.277.11.925 · Cited by 668
Degn, K. B., Juhl, C. B., Sturis, J., Jakobsen, G., Brock, B., Chandramouli, V., Rungby, J., Landau, B. R., & Schmitz, O. (2004) · Diabetes · doi:10.2337/diabetes.53.5.1187 · Cited by 427
Self-citationMadsbad, S., Schmitz, O., Ranstam, J., Jakobsen, G., Matthews, D. R., & on behalf of the NN2211-1310 International Study Group (2004) · Diabetes Care · doi:10.2337/diacare.27.6.1335 · Cited by 312
Self-citationRolin, B., Larsen, M. O., Gotfredsen, C. F., Deacon, C. F., Carr, R. D., Wilken, M., & Knudsen, L. B. (2002) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00030.2002 · Cited by 281
Sturis, J., Gotfredsen, C. F., Rømer, J., Rolin, B., Ribel, U., Brand, C. L., Wilken, M., Wassermann, K., Deacon, C. F., Carr, R. D., et al. (2003) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0705397 · Cited by 202
Nauck, M. A., Hompesch, M., Filipczak, R., Le, T., Zdravkovic, M. D., & Gumprecht, J. J. (2006) · Experimental and Clinical Endocrinology & Diabetes · doi:10.1055/s-2006-924230 · Cited by 144
Self-citation
Cited by
Drucker, D. J., & Nauck, M. A. (2006) · The Lancet · doi:10.1016/s0140-6736(06)69705-5 · Cited by 3,896
Glucagon-like peptide 1 (GLP-1)
Müller, T. D., Finan, B., Bloom, S. R., D'Alessio, D., Drucker, D. J., Flatt, P. R., Fritsche, A., Gribble, F., Grill, H. J., Habener, J. F., et al. (2019) · Molecular Metabolism · doi:10.1016/j.molmet.2019.09.010 · Cited by 1,868
Astrup, A., Rössner, S., Van Gaal, L., Rissanen, A., Niskanen, L., Al Hakim, M., Madsen, J., Rasmussen, M. F., & Lean, M. E. (2009) · The Lancet · doi:10.1016/s0140-6736(09)61375-1 · Cited by 1,163
Nauck, M., Frid, A., Hermansen, K., Shah, N. S., Tankova, T., Mitha, I. H., Zdravkovic, M., Düring, M., Matthews, D. R., & for the LEAD-2 Study Group (2009) · Diabetes Care · doi:10.2337/dc08-1355 · Cited by 1,129
Self-citationGarber, A., Henry, R., Ratner, R., Garcia-Hernandez, P. A., Rodriguez-Pattzi, H., Olvera-Alvarez, I., Hale, P. M., Zdravkovic, M., & Bode, B. (2009) · The Lancet · doi:10.1016/s0140-6736(08)61246-5 · Cited by 1,057
Self-citation
Metadata
- Authors
- Vilsbøll, T., Zdravkovic, M., Le-Thi, T., Krarup, T., Schmitz, O., Courrèges, J.-P., Verhoeven, R., Bugánová, I., & Madsbad, S.
- Venue
- Diabetes Care
- Publisher
- American Diabetes Association
- Published
- 2007-06-01
- Volume
- 30
- Issue
- 6
- Pages
- 1608-1610
- ISSN
- 0149-5992 (ISSN-L)
- 1935-5548
- OpenAlex
- W2103525547
- Cited by
- 468
- References
- 12
- FWCI
- 43.86
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Liraglutide, a Long-Acting Human Glucagon-Like Peptide-1 Analog, Given as Monotherapy Significantly Improves Glycemic Control and Lowers Body Weight Without Risk of Hypoglycemia in Patients With Type 2 Diabetes. https://app.cochat.ai/papers/10.2337/dc06-2593
- The paper
- Vilsbøll, T., Zdravkovic, M., Le-Thi, T., Krarup, T., Schmitz, O., Courrèges, J.-P., Verhoeven, R., Bugánová, I., & Madsbad, S. (2007). Liraglutide, a Long-Acting Human Glucagon-Like Peptide-1 Analog, Given as Monotherapy Significantly Improves Glycemic Control and Lowers Body Weight Without Risk of Hypoglycemia in Patients With Type 2 Diabetes. Diabetes Care. https://doi.org/10.2337/dc06-2593
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
